Long-term efficacy and safety of dolutegravir/ lamivudine in virologically suppressed persons with HIV and history of resistance to lamivudine: week 96 results of VOLVER clinical trial

Conference Reports for NATAP

HIV Drug Therapy Glasgow 2024
10-13 November


Long-term efficacy and safety of dolutegravir/ lamivudine in virologically suppressed persons with HIV and history of resistance to lamivudine: week 96 results of VOLVER clinical trial - GESIDA 11820